Back to main site
2nd Annual Outsourcing in Clinical Trials Southeast
7-8 May 2013, Embassy Suites Raleigh-Durham/Research Triangle, Cary, NCOutsourcing in Clinical Trials Southeast was Arena International’s best launch event of 2012 and it is set to become one of the most successful conferences in the Outsourcing series. Catering to the industry based in North Carolina and surrounding states, this conference offers a fantastic local event for the Southeast hub.
With a focus on offering new and worthwhile content, we will soon be welcoming an OCT Southeast Advisory Board, made up from experts in the local industry who will play a key role in ensuring the agenda content is exactly what clinical outsourcing professionals need to know so that attendees can be sure their experience will be truly valuable.
Latest News
2nd Annual Outsourcing in Clinical Trials Southeast
The 2nd Annual Outsourcing in Clinical Trials Conference Southeast is a fantastic platform for biotech, pharma and medical device professionals from the RTP area to discuss the specific challenges they face on day-to-day basis. The beauty of this unique event is its local reach and its specifically tailored topics which will help you to achieve better results from your outsourcing programs.
Upcoming OCT events 2013-2014
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
Who Should Attend OCT Southeast?
Primary delegates for this event are those with responsibility for outsourcing in biotech, pharma and medical device companies around the Research Triangle. Including;CEO/CMO/CSO/CFOGlobal Head, Head, VP, Director:Clinical OperationsClinical ResearchOutsourcing / sourcing / procurement / alliancesGlobal Head, Head, VP, Director:Clinical TrialsProject Management
Testimonials
Testimonials from the 2012 Outsourcing in Clinical Trials Southeast Conference……..
OCT Southeast 2013 Testimonials
You really chose a great group of presenters who were knowledgeable, well-spoken and approachable. The talks kept building on the theme which assured a great learning experience. The round table idea was a great success in this setting. Bravo
OCTSE 2013: Conference Provided Great Setting to Discuss the Clinical FSP Model and Other Issues
Last week, our team was fortunate enough to be able to join 28 other exhibitors at the second annual Outsourcing in Clinical Trials Southeast conference. Held at the Embassy Suites in Research Triangle Park, N.C., the event attracted a diverse blend of biotech, pharma and medical device companies.
-
Takeda begins TOURMALINE-MM2 phase 3 trial of multiple myeloma drug
Takeda Pharmaceutical Company has began its TOURMALINE-MM2 phase 3 trial of MLN9708 in patients with newly diagnosed multiple myeloma.
-
Protalex reports positive interim review of phase 1b rheumatoid arthritis trial
Clinical-stage biopharmaceutical company Protalex has reported positive interim review of phase 1b trial of PRTX-100 in rheumatoid arthritis (RA) by an independent data safety monitoring committee.
-
Prosonix commences Phase 2 study of chronic obstructive pulmonary disease drug candidate
Speciality pharmaceutical company Prosonix has began the PSX1002 Phase 2 study in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
-
Jennerex completes enrolment in Phase 2b liver cancer trial of Pexa-Vec
Jennerex Biotherapeutics has announced completion of enrolment in Phase 2b trial of Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of liver cancer.
-
Sanofi and Regeneron announce positive Phase 2a Results of Dupilumab in Asthma patients
Dupilumab targets the alpha subunit of the interleukin 4 receptor (IL-4R alpha), which modulates signaling of both IL-4 and IL-13, drivers of Th2 (Type 2 helper T cell) immune response.
-
AbbVie begins Phase 3 diabetic nephropathy study of atrasentan
Research-based biopharmaceutical company AbbVie has started Phase 3 in study of investigational compound atrasentan on renal outcomes in patients with diabetic nephropathy.
-
R-Tech begins patient enrolment in Phase I/II severe dry eye study
R-Tech Ueno has started patient enrolment in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in the US for treating severe dry eye.
-
Pfizer ends inotuzumab ozogamicin Phase 3 non-Hodgkin lymphoma study
Pfizer has stopped the Phase 3 randomised, open-label study (B1931008) of inotuzumab ozogamicin in relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL).
